These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 3137469)

  • 1. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
    Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
    J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
    Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
    Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
    Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
    Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
    Jurga L; Misurová E; Vancík J
    Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
    Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
    J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
    Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M
    Cancer Treat Rev; 1990 Sep; 17(2-3):161-3. PubMed ID: 2125531
    [No Abstract]   [Full Text] [Related]  

  • 10. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
    Green MD
    Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
    Valero V; Buzdar AU; Theriault RL; Azarnia N; Fonseca GA; Willey J; Ewer M; Walters RS; Mackay B; Podoloff D; Booser D; Lee LW; Hortobagyi GN
    J Clin Oncol; 1999 May; 17(5):1425-34. PubMed ID: 10334527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICRF-187 and doxorubicin-induced cardiac toxicity.
    N Engl J Med; 1989 Feb; 320(6):399-400. PubMed ID: 2492370
    [No Abstract]   [Full Text] [Related]  

  • 15. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML; Moiceenko VM; Orlova RV
    Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
    Zhang J; Herman EH; Ferrans VJ
    Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.